Having trouble accessing articles? Reset your cache.

FDA approves Amarin’s Vascepa to reduce CV risk in narrower population

FDA approved Amarin’s Vascepa for cardiovascular risk reduction Friday, though the label is slightly more restrictive than what the company had been aiming for.

Shares of Amarin Corp. plc (NASDAQ:AMRN) gained

Read the full 314 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE